

triptorelin 11.25mg injection (Decapeptyl SR[®]) (No. 207/05)

Ipsen Ltd

Product Update

9 September 2005

The Scottish Medicines Consortium has completed its assessment of the above product and advises NHS Boards and ADTCs on its use in NHS Scotland. The advice is summarised as follows:

ADVICE: following an abbreviated submission

Triptorelin 11.25mg injection every 3 months (Decapeptyl SR[®]) is accepted for use within NHS Scotland for the treatment of endometriosis in patients for whom the use of triptorelin is appropriate and who would benefit from reduced frequency of administration compared with triptorelin 3mg injection every 4 weeks (Decapeptyl).

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at after evaluation of the evidence submitted by the company. It is provided to inform the considerations of Area Drug & Therapeutics Committees and NHS Boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

*This assessment is based on data submitted by the applicant company up to and including **Tuesday 12 July 2005***

**Chairman
Scottish Medicines Consortium**